Trials / Recruiting
RecruitingNCT06361927
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC.
Detailed description
This study is a study of SSGJ-707 monotherapy in First-line PD-L1 Positive advanced NSCLC Patients. This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC. Each cohort will assess the efficacy and safety of the preset several dose levels of SSGJ-707 in advanced NSCLC Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SSGJ-707 | bispecific antibody |
Timeline
- Start date
- 2024-05-15
- Primary completion
- 2025-06-01
- Completion
- 2025-07-01
- First posted
- 2024-04-12
- Last updated
- 2024-05-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06361927. Inclusion in this directory is not an endorsement.